Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dexamethasone Sodium Phosphate

FDA-approved product (ointment, ophthalmic), marketed as Decadron, Dexacen-4, Dexacort and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Dexamethasone Sodium Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Adrenal gland disease
  • Adrenal gland hyperfunction
  • Adrenocortical insufficiency
  • Allergic conjunctivitis
  • Allergic rhinitis
  • Ankylosing spondylitis
  • Aplastic anemia
  • Asthma
  • Atopic eczema
  • Autoimmune thrombocytopenic purpura
  • Brain edema
  • Bursitis
  • Cancer
  • Chorioretinitis
  • Choroiditis
  • and 66 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids; Corticosteroids, moderately potent (group ii); Corticosteroids, moderately potent, other combinations; Corticosteroids, combinations for treatment of acne
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli36.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dexamethasone Sodium Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dexamethasone Sodium Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

    NCT00458822 · start 2007-02

    Registered record
    Registry ID
    NCT00458822
    Conditions
    Multiple Myeloma and Plasma Cell Neoplasm
    Interventions
    bortezomib; dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-02
    Completion
    2015-03
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma and Plasma Cell Neoplasm
    Interventionbortezomib; dexamethasone
    PhasePhase 2
    Registry statusCompleted

  • A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome

    NCT00201643 · start 2003-11

    Registered record
    Registry ID
    NCT00201643
    Conditions
    Preterm Delivery
    Interventions
    Betamethasone or Dexamethasone (2nd course of ACS); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-11
    Completion
    2008-02
    Enrolment
    437

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreterm Delivery
    InterventionBetamethasone or Dexamethasone (2nd course of ACS); Placebo
    PhasePhase 4
    Registry statusCompleted

  • Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy

    NCT00205751 · start 2001-08

    Registered record
    Registry ID
    NCT00205751
    Conditions
    Multiple Myeloma
    Interventions
    Thalidomide/Dexamethasone vs Melphalan/Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2001-08
    Completion
    2009-10
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionThalidomide/Dexamethasone vs Melphalan/Prednisone
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

    NCT00006345 · start 1999-11

    Registered record
    Registry ID
    NCT00006345
    Conditions
    Drug/Agent Toxicity by Tissue/Organ; Lymphoma
    Interventions
    denileukin diftitox; dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-11
    Completion
    2004-03
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug/Agent Toxicity by Tissue/Organ; Lymphoma
    Interventiondenileukin diftitox; dexamethasone
    PhasePhase 2
    Registry statusCompleted

  • Dose-Dense Therapy in Aggressive Lymphoma

    NCT00517894

    Registered record
    Registry ID
    NCT00517894
    Conditions
    Lymphoma
    Interventions
    CEOP/IMVP-Dexa chemotherapy
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    InterventionCEOP/IMVP-Dexa chemotherapy
    PhaseNot recorded
    Registry statusNo longer available